Home  >  Research  >  Labs  >  Cancer Program

OVERVIEW

The Cancer Program is led by Professor Pilar Blancafort.

The mission of the Perkins Cancer Program is to transform cancer outcomes by uncovering the molecular and cellular causes, advancing early detection methods, and developing precision treatments for poor prognosis cancers, specifically women’s cancers (breast, ovarian), liver cancer, pancreatic cancer, melanoma and head and neck cancers.

Perkins Cancer Researchers are working towards understanding cancer, detecting it sooner and treating it smarter by: ​

  1. Uncovering how cancer starts, grows and resists treatment, to find new ways to stop it in its tracks.​
  2. Creating better tests and tools to detect cancer sooner and predict how it might respond to treatment.​
  3. Developing personalised cancer treatments, from new medicines to advanced immunotherapy, giving patients the best chance at beating even the toughest cancers.​
  4. Understanding the biological factors influencing poorer outcomes in Aboriginal people with cancer.​

Perkins researchers have made major discoveries in the field of cancer including uncovering the SLIRP gene which controls hormone production in breast and prostate cancers, the tumour suppressor gene HLS5 and a process for normalising blood vessels in tumours to allow more effective absorption of cancer-combating drugs. Detailed information about our cancer laboratories can be found below.

Professor Pilar Blancafort

Professor Pilar Blancafort

Cancer Epigenetics (Program Leader - Cancer)

Read more

RESEARCH NEWS & EVENTS

Rare disease researcher Professor Gina Ravenscroft recognised with prestigious Aspire Award

Business Events Perth has announced the 2026 Aspire Award recipients, representing excellence across each of the program’s partner categories in recognition of Western Australia’s leading researchers, academics and professionals.  The…

Read More

Perkins researchers win big at the WA Innovators of the Year Awards

Prof Shirley Jansen (left), A/Prof Juliana Hamzah (middle), Atherid Therapeutics CEO Meghan Thomas (right) Last night Associate Professor Juliana Hamzah, Professor Shirley Jansen AM and Atherid Therapeutics were the recipients…

Read More

Funding to improve cardiovascular health outcomes

Researchers developing innovative technology for early heart disease detection have received more than $298,000 from the Heart Foundation’s 2026 research funding program. They have been awarded Vanguard Grants to test…

Read More

Help WA's best medical researchers beat the world's toughest diseases.